Quantitative assessment of P-glycoprotein function in the rat blood–brain barrier by distribution volume of [11C]verapamil measured with PET

This publication has 28 references indexed in Scilit:

• An oncological view on the blood–testis barrier
  The Lancet Oncology, 2002
• Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein
  Anti-Cancer Drugs, 1999
• Complete in vivo reversal of P‐glycoprotein pump function in the blood‐brain barrier visualized with positron emission tomography
  British Journal of Pharmacology, 1998
• HIV-1 Protease Inhibitors Are Substrates for theMDR1 Multidrug Transporter
  Biochemistry, 1998
• The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
  Journal of Clinical Investigation, 1998
• Pharmacokinetics of Cyclosporine as a Function of Energy-Protein Deficiency in Children with Chronic Renal Failure
  The Journal of Clinical Pharmacology, 1997
• P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.
  Journal of Clinical Investigation, 1996
• Short Communication
  Therapeutic Drug Monitoring, 1995
• Increased neurotoxicity with VAD-cyclosporin in multiple myeloma
  The Lancet, 1993
• Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-¹¹C-Methyl]-(−)-Cocaine PET Studies in Human Subjects
  Journal of Cerebral Blood Flow & Metabolism, 1990